GlycoMimetics Inc. (GLYC)
GlycoMimetics Statistics
Share Statistics
GlycoMimetics has 64.51M shares outstanding. The number of shares has increased by 0.05% in one year.
Shares Outstanding | 64.51M |
Shares Change (YoY) | 0.05% |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | 27.57% |
Shares Floating | 56.06M |
Failed to Deliver (FTD) Shares | 14.31K |
FTD / Avg. Volume | 0.89% |
Short Selling Information
The latest short interest is 5.64M, so 8.74% of the outstanding shares have been sold short.
Short Interest | 5.64M |
Short % of Shares Out | 8.74% |
Short % of Float | 9.88% |
Short Ratio (days to cover) | 1.07 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -2.8. GlycoMimetics's PEG ratio is 0.
PE Ratio | 0 |
Forward PE | -2.8 |
PS Ratio | 0 |
Forward PS | 1.1 |
PB Ratio | 0 |
P/FCF Ratio | 0 |
PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for GlycoMimetics Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.92, with a Debt / Equity ratio of 0.01.
Current Ratio | 1.92 |
Quick Ratio | 1.92 |
Debt / Equity | 0.01 |
Total Debt / Capitalization | 1.24 |
Cash Flow / Debt | -465.23 |
Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0% and return on capital (ROIC) is -744.17%.
Return on Equity (ROE) | 0% |
Return on Assets (ROA) | 0% |
Return on Capital (ROIC) | -744.17% |
Revenue Per Employee | $0 |
Profits Per Employee | $0 |
Employee Count | 4 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -91.45% in the last 52 weeks. The beta is 1.81, so GlycoMimetics's price volatility has been higher than the market average.
Beta | 1.81 |
52-Week Price Change | -91.45% |
50-Day Moving Average | 0.26 |
200-Day Moving Average | 0.25 |
Relative Strength Index (RSI) | 45.39 |
Average Volume (20 Days) | 1.61M |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | -40.04B |
Net Income | 0 |
EBITDA | -40.04B |
EBIT | n/a |
Earnings Per Share (EPS) | -0.59 |
Balance Sheet
The company has 10.72M in cash and 66.84M in debt, giving a net cash position of -56.12M.
Cash & Cash Equivalents | 10.72M |
Total Debt | 66.84M |
Net Cash | -56.12M |
Retained Earnings | -494.36B |
Total Assets | 11.09M |
Working Capital | 5.31M |
Cash Flow
In the last 12 months, operating cash flow was -31.1B and capital expenditures -9.97K, giving a free cash flow of -31.11B.
Operating Cash Flow | -31.1B |
Capital Expenditures | -9.97K |
Free Cash Flow | -31.11B |
FCF Per Share | -482.47 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
GLYC does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -226.92% |
FCF Yield | -184818.48% |
Analyst Forecast
Currently there are no analyst rating for GLYC.
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Scores
Altman Z-Score | -70.21 |
Piotroski F-Score | 2 |